Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 7, 2026, 2:32 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1177–1200 of 21,991 matching trials from the live ClinicalTrials.gov search.

Filters: Recruiting Clear all

Conditions: Recurrent Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Recurrent High Grade B-Cell Lymphoma, Not Otherwise Specified, Recurrent Primary Mediastinal Large B-Cell Lymphoma, Recurrent Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma, Refractory Diffuse Large B-Cell Lymphoma, Not Otherwise Specified, Refractory High Grade B-Cell Lymphoma, Not Otherwise Specified, Refractory Primary Mediastinal Large B-Cell Lymphoma, Refractory Transformed Indolent B-Cell Non-Hodgkin Lymphoma to Diffuse Large B-Cell Lymphoma
Interventions: Autologous Hematopoietic Stem Cell Transplantation, Biopsy Procedure, Biospecimen Collection, Bone Marrow Aspiration, Bone Marrow Biopsy, Computed Tomography, Epcoritamab, Gemcitabine, Oxaliplatin, Positron Emission Tomography, Rituximab; Procedure · Biological · Drug
Lead sponsor: City of Hope Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 43 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 3
States / cities: Duarte, California • Newnan, Georgia • Zion, Illinois

Conditions: Type 1 Diabetes (T1D), Sleep Health
Interventions: Sleep Health and Circadian Timing Intervention; Behavioral
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 14 Years to 19 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2029
U.S. locations: 1
States / cities: Aurora, Colorado

Conditions: Healthy Participants
Interventions: Elecoglipron Reference Formulation Dose A, Elecoglipron Test formulation 1 Dose A, Elecoglipron Reference Formulation Dose B, Elecoglipron Test formulation 1 Dose B, Elecoglipron Test formulation 2 Dose A, Elecoglipron Test formulation 2 Dose B; Drug
Lead sponsor: AstraZeneca; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 152 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026
U.S. locations: 2
States / cities: Glendale, California • Brooklyn, Maryland

Conditions: Central Nervous System
Interventions: NIH Toolbox Cognitive Battery; Other
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 4 Years to 21 Years
Enrollment: 80 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2015 – 2032
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Multiple Myeloma
Interventions: Etentamig, Lenalidomide, Daratumumab, Dexamethasone; Drug
Lead sponsor: AbbVie; Industry
Eligibility: 18 Years and older
Enrollment: 680 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2042
U.S. locations: 17
States / cities: Scottsdale, Arizona • Los Angeles, California • Denver, Colorado + 12 more

Conditions: Depressive Disorder, Treatment-Resistant, Treatment Resistant Depression (TRD)
Interventions: Ketamine, Normal Saline; Drug
Lead sponsor: Mayo Clinic; Other
Eligibility: 18 Years to 65 Years
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Rochester, Minnesota

Conditions: Adverse Drug Reaction (ADR), Polypharmacy Patients
Interventions: Not listed
Lead sponsor: Texas A&M University; Other
Eligibility: 18 Years to 100 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Bryan, Texas

Conditions: Cerebral Palsy
Interventions: Umbilical or placental derived mesenchymal stem cells; Biological
Lead sponsor: The Foundation for Orthopaedics and Regenerative Medicine; Other
Eligibility: Not listed
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Naples, Florida

Conditions: Chronic Kidney Disease
Interventions: NNC0519-0130, Placebo, Semaglutide; Drug
Lead sponsor: Novo Nordisk A/S; Industry
Eligibility: 18 Years and older
Enrollment: 465 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 18
States / cities: San Dimas, California • San Ramon, California • Aurora, Colorado + 14 more

Conditions: Obstructive Sleep Apnea
Interventions: Propofol sedation, Dexmedetomidine sedation; Drug
Lead sponsor: Erin Kirkham; Other
Eligibility: 3 Years to 11 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Breast Cancer, Kidney Neoplasms, Liver Neoplasms
Interventions: contrast agent perflutren lipid, Ultrasound Imaging; Drug · Device
Lead sponsor: UNC Lineberger Comprehensive Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 40 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chapel Hill, North Carolina

Conditions: Type 1 Diabetes
Interventions: T1CARE; Behavioral
Lead sponsor: Yale University; Other
Eligibility: 18 Years to 40 Years
Enrollment: 114 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 2
States / cities: New Haven, Connecticut

Conditions: Obesity Prevention
Interventions: Not listed
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: Not listed
Enrollment: 3,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2045
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Hispanic Americans, Chronic Disease Prevention, Cancer Prevention, Fruit and Vegetable Consumption
Interventions: The Value of Our Health; Behavioral
Lead sponsor: University of Washington; Other
Eligibility: 18 Years and older
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2029
U.S. locations: 2
States / cities: Granger, Washington • Seattle, Washington

Conditions: Pregnancy
Interventions: Simulated stimuli, Stress Management; Behavioral
Lead sponsor: Nova Southeastern University; Other
Eligibility: 21 Years to 37 Years · Female only
Enrollment: 50 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Davie, Florida

Conditions: Diabetes Mellitus, Type 2
Interventions: Peer Coaching - Peer Participants A, Peer Coaching - Peer Participants B, Peer Coaching - Peer Participants C, Peer Coaching - Peer Participants D; Behavioral
Lead sponsor: The University of Texas Medical Branch, Galveston; Other
Eligibility: 55 Years and older
Enrollment: 25 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2027
U.S. locations: 2
States / cities: Bowling Green, Kentucky • Hazard, Kentucky

Conditions: Mesothelioma, Mesothelioma; Lung, Mesotheliomas Pleural, Mesothelioma Malignant Advanced, Mesothelioma, Malignant
Interventions: Partial Pleurectomy; Procedure
Lead sponsor: University of Chicago; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Atrial Fibrillation (AF)
Interventions: Half-Dose of novel OAC, Low-dose ASA; Drug
Lead sponsor: Texas Cardiac Arrhythmia Research Foundation; Other
Eligibility: 18 Years and older
Enrollment: 234 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Austin, Texas

Conditions: Severe Aplastic Anemia
Interventions: Fludarabine, Cyclophosphamide, Total Body Irradiation, Rabbit ATG; Drug · Radiation
Lead sponsor: Northside Hospital, Inc.; Other
Eligibility: 1 Year to 75 Years
Enrollment: 20 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2028
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Triple Negative Breast Cancer (TNBC)
Interventions: RESTORE, Enhanced Usual Care; Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years and older
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Hematologic Diseases
Interventions: Not listed
Lead sponsor: Invivoscribe, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 2,000 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 1
States / cities: San Diego, California

Conditions: Sleep, Nightshift Work
Interventions: Single-Sensor Tracking (In-Lab), Multi-Sensor Sleep Tracking (In-Lab), Multi-Sensor Sleep Tracking (At-Home); Other
Lead sponsor: Henry Ford Health System; Other
Eligibility: 18 Years and older
Enrollment: 100 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2026 – 2031
U.S. locations: 1
States / cities: Novi, Michigan

Conditions: LCA5
Interventions: AAV8.hLCA5; Biological
Lead sponsor: Opus Genetics, Inc; Industry
Eligibility: 4 Years and older
Enrollment: 22 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 2
States / cities: Philadelphia, Pennsylvania • Dallas, Texas

Conditions: Myopia, Astigmatism
Interventions: Ray tracing guided LASIK surgery; Device
Lead sponsor: Stanford University; Other
Eligibility: 22 Years to 59 Years
Enrollment: 62 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2029
U.S. locations: 1
States / cities: Palo Alto, California

Search by objective public record fields.

Epcoritamab, Rituximab, Gemcitabine and Oxaliplatin (R-GemOx) as Salvage Therapy Before Autologous Stem Cell Transplant for the Treatment of Relapsed/Refractory Diffuse Large B-Cell Lymphoma

Type 1 Diabetes REst for Metabolic Health

A Study to Investigate the Relative Bioavailability and Safety of Different Oral Formulations of Elecoglipron in Healthy Participants

Computer-based Neurocognitive Assessment in Children With Central Nervous System Tumors Receiving Proton Beam Radiation Therapy

A Study to Assess A Change in Disease Activity and Adverse Events of Intravenous Etentamig and Daratumumab (Etentamig+D) Compared to Daratumumab, Lenalidomide, and Dexamethasone (DRd) in Adult Participants With Newly Diagnosed Multiple Myeloma Not Eligible for Transplant

Intravenous Ketamine for Treatment-Resistant Depression

IPGx PILOT Whole Genome Sequencing Extension Cohort

Safety of Cultured Umbilical or Placental Derived Mesenchymal Stem Cell Intravenous Infusion for CP

A Research Study Comparing How Well Different Doses of the Medicine NNC0519-0130 Can Reduce Kidney Damage in People Living With Chronic Kidney Disease

Dexmedetomidine Versus Propofol Sedation for Drug-Induced Sleep Endoscopy in Pediatric Obstructive Sleep Apnea

Translation of Acoustic Angiography: Contrast Enhanced Super Resolution (CESR) Imaging

T1CARE: A Trial of a Novel Intervention to Address Social Determinants of Health in Young Adults With Type 1 Diabetes

Pennington Generation Cohort

Nuestro Valor: Increasing Healthier Food Access for Rural Latino Communities Through a Food Retail Intervention

Mitigating Response to Stressors in Pregnant Women

OASIS: Peer Support for T2DM in Appalachia (Peer Coaches)

Partial Pleurectomy (Surgery) for Unresectable Pleural Mesothelioma

Optimal Anti-Thrombotic Management Following Percutaneous Left Atrial Appendage Occlusion

Haploidentical Bone Marrow Transplant With Post-Transplant Cyclophosphamide for Patients With Severe Aplastic Anemia

A Nurse-Led, Coping and Supportive Intervention for Patients With Triple-Negative Breast Cancer

The Use of Residual De-identified Specimens and/or Samples From Patients for Clinical Research

The Use of Multiple Sensors to Track Sleep in Nightshift Workers

Safety and Tolerability Subretinal OPGx-001 for LCA5-Associated Inherited Retinal Degeneration (LCA5-IRD) and Non-interventional Arm With Untreated Patients

SMILE Surgery in One Eye Compared to Ray Tracing-guided LASIK Surgery in the Fellow Eye